Latest Breaking News On - Ulrike gnad vogt - Page 4 : comparemela.com

CureVac announces start of phase 1 trial of modified COVID-19 mRNA vaccine candidate

CureVac announces start of phase 1 trial of modified COVID-19 mRNA vaccine candidate
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United kingdomUlrike gnad vogt

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Busin

Issuer: CureVac / Key word(s): Quarter Results18.08.2022 / 13:05 The issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update Delivering on broad 2022 second-generation vaccine development program.

United statesUnited kingdomUlrike gnad vogtMyriam mendilaSarah fakihFranz werner haasPierre kemulaDevelopment officerRna vaccine programCurevac incGerman regional courtDistribution servicesExchange commissionCorporate developmentCorporate communicationsCurevac corporate services gmb

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Issuer: CureVac / Key word(s): Study18.08.2022 / 13:00 The issuer is solely responsible for the content of this announcement.CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate  Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Aust.

United statesUnited kingdomUlrike gnad vogtSarah fakihExchange commissionCurevac incCorporate communicationsCurevac corporate services gmbDistribution servicesVac starts phaseChief development officerVice president corporate communicationsCurevac manufacturing gmbhCurevac swissCurevac corporate services gmbhCurevac belgium

DGAP-News: CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Issuer: CureVac / Key word(s): Study CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate.

United kingdomUlrike gnad vogtSarah fakihCorporate communicationsUnited statesCurevac starts phaseChief development officerVice president corporate communicationsManager communications

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studiesPhase

United statesUnited kingdomUlrike gnad vogtMyriam mendilaSarah fakihFranz werner haasPierre kemulaDevelopment officerRna vaccine programCurevac incGerman regional courtExchange commissionCorporate developmentCorporate communicationsCurevac corporate services gmbMrna technology